NetraMark Holdings Inc C.AIAI

Alternate Symbol(s): AINMF

Technology Software - Application

NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.

CSE:AIAI - Post by User

NetraMark Holdings Inc > Conference Call Dec 5 9:00 am ET

<< Previous

Bullboard Posts

Next >>

Post by windymayor1on Dec 02, 2024 4:55pm

127 Views

Post# 36341582

Conference Call Dec 5 9:00 am ET

We are pleased to invite you to a call hosted by NetraMark CEO, George Achilleos who will sit down with Dr. Luca Pani, Netramark's Chief Innovation and Regulatory Officer (brief bio below). Dr. Pani will discuss his expert insight into how and where NetraMark will fit into the clinical trial arena, from a regulatory perspective.

Event Details:
• Date: Dec 5, 2024
• Time: 9 am ET
• Duration: 45 minutes
• Access Information: Platform - Google Meet - https://meet.google.com/hgp-zybc-spc?hs=224

Join by phone

(CA) +1 647-733-3671
PIN: 962624297

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo